John M. Hamm's Insider Trades & SAST Disclosures
John M. Hamm's most recent trade in Cumberland Pharmaceuticals Inc. was a trade of 5,930 Common Stock done at an average price of $5.5 . Disclosure was reported to the exchange on March 16, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern John M. Hamm.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland Pharmaceuticals... | John M. Hamm | VP Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.46 per share. | 16 Mar 2025 | 5,930 | 20,073 (0%) | 0% | 5.5 | 32,378 | Common Stock |
| Cumberland Pharmaceuticals... | John M. Hamm | VP Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2025 | 2,750 | 15,250 | - | - | Options (right to buy) | |
| Cumberland Pharmaceuticals... | John M. Hamm | VP Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2024 | 5,500 | 12,500 | - | - | Options (right to buy) | |
| Cumberland Pharmaceuticals... | John M. Hamm | VP Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.81 per share. | 23 Mar 2024 | 445 | 26,003 (0%) | 0% | 1.8 | 805 | Common Stock |
| Cumberland Pharmaceuticals... | Hamm M. John | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.67 per share. | 27 Nov 2023 | 352 | 26,448 (0%) | 0% | 1.7 | 588 | Common Stock |
| Cumberland Pharmaceuticals... | John M. Hamm | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 2,000 | 7,000 | - | - | Options (right to buy) | |
| Cumberland Pharmaceuticals... | John M. Hamm | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 2.59 per share. | 16 Mar 2022 | 20,000 | 26,800 (0%) | 0% | 2.6 | 51,800 | Common Stock |
| Cumberland Pharmaceuticals... | John M. Hamm | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 2,000 | 2,000 | - | - | Options (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges